Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology

Adoptive cell immunotherapy with chimeric antigen receptor T (CAR‐T) cell has brought a revolutionary means of treatment for aggressive diseases such as hematologic malignancies and solid tumors. Over the last decade, the United States Food and Drug Administration (FDA) approved five types of CAR‐T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biotechnology and bioengineering 2021-10, Vol.118 (10), p.3691-3705
Hauptverfasser:	Sadeqi Nezhad, Muhammad, Yazdanifar, Mahboubeh, Abdollahpour‐Alitappeh, Meghdad, Sattari, Arash, Seifalian, Alexander, Bagheri, Nader
Format:	Artikel
Sprache:	eng
Schlagworte:	Adoptive Transfer Antigens Antitumor activity cancers CAR‐T cell Cell therapy Chimeric antigen receptors Clinical trials CRISPR CRISPR-Cas Systems CRISPR/Cas9 Genetic engineering Hematologic Neoplasms - genetics Hematologic Neoplasms - therapy Humans Immunotherapy Lymphocytes Lymphocytes T Receptors, Chimeric Antigen - genetics Receptors, Chimeric Antigen - therapeutic use Side effects Solid tumors Technology utilization therapeutic Tumor microenvironment Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!